Shares of JB Chemicals & Pharmaceuticals Ltd are likely to remain in focus following media reports from CNBC-Awaaz suggest a large block deal has been launched by promoter group entity Tau Investment Holdings Pte. Ltd. According to the reports, the proposed deal involves the sale of up to 10.2% of the company’s equity, amounting to around ₹2,575 crore.
As per the indicative terms, the shares are being offered at a price of ₹1,625 apiece — representing a discount of nearly 4.9% to JB Chemicals’ last traded price. The block deal is expected to see heightened participation from institutional investors, given the size and pricing.
Additionally, the reports suggest that a 90-day lock-up period has been placed on any further sale of shares by the seller, Tau Investment Holdings, which signals a near-term halt on additional stake dilution.
Tau Investment Holdings, backed by private equity firm KKR, had acquired a controlling stake in JB Chemicals back in 2020. Since then, the company has seen notable improvements in performance and geographical expansion, particularly in the chronic therapies segment.
